San Antonio Breast Cancer Symposium

Posters Show Efficacy for Combination Therapies With Trastuzumab Biosimilars in Breast Cancer

January 4th 2024

Posters from San Antonio Breast Cancer Symposium 2023 found that combination therapies featuring trastuzumab biosimilars and other common cancer medicines were safe and effective in patients with breast cancer.

SABCS Posters Evaluate Real-World Outcomes Associated With Ogivri

December 14th 2023

Article

Two Taiwanese posters presented at the San Antonio Breast Cancer Symposium (SABCS) 2023 annual meeting evaluated the real-world implications of using trastuzumab biosimilars, particularly Ogivri (trastuzumab-dkst) in patients with HER2-postive breast cancer.

Biosimilar-Gedatolisib Combo Elicits Response in Resistant mBC

December 14th 2021

Article

In metastatic breast cancer (mBC) resistant to multiple lines, Herzuma (a trastuzumab biosimilar) plus gedatolisib, an mTOR/PI3K signaling pathway inhibitor, demonstrated value.

Patient-Provider Surveys Elucidate Biosimilar Switching Process in Oncology

December 13th 2021

Article

After a switch to a biosimilar, patients and their oncologists may not always agree on how well the switch was described or whether the patient felt involved.

Ontruzant Biosimilar Demonstrates Equivalence to Herceptin in 5-Year Study

December 9th 2021

Article

The trial included "drifted" (nonstandard) reference product, forcing a stratified analysis to yield relevant data.

EirGenix Trastuzumab Biosimilar Candidate Demonstrates Equivalence in HER2-Positive Breast Cancer

December 8th 2021

Article

A trastuzumab biosimilar candidate demonstrated equivalence to Herceptin in patients with early-stage human epidermal growth factor receptor 2 (HER2)–breast cancer.

The Top 5 Biosimilar Articles From SABCS 2020

January 31st 2021

Video

Here are the top 5 biosimilar articles from SABCS 2020.

Data From HERITAGE Confirm PK Biosimilarity for Ogivri

January 9th 2021

Article

Pharmacokinetic (PK) parameters matched up with those of reference trastuzumab in an extended analysis of data from the HERITAGE trial.

Investigators Chart ABP 980 Biosimilar Uptake in European Clinics

January 4th 2021

Article

Among patients treated for metastatic breast cancer, 40% switched to ABP 980.

Investigators Demonstrate Dramatic Rise in Trastuzumab Biosimilar Use

December 15th 2020

Article

In little over 1 year of use in patients with breast cancer, trastuzumab biosimilars have seen rapid growth in uptake.